Oncology Companion Diagnostic Market Size, Share and Growth Outlook 2026: By Product and Service Type (Products, Services), By Technology Type, By Disease, By Sample Type, By End-User, Companies to 2034.
The global Oncology Companion Diagnostic Market size is forecast to increase from $5.83 Billion in 2026 to $11.84 Billion in 2034 at a CAGR of 9.26% between 2026 and 2034.
The Oncology Companion Diagnostic market report provides detailed analysis and outlook of Oncology Companion Diagnostic segments including By Product and Service Type (Products, Services ), By Technology Type (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), In Situ Hybridization (ISH) / Fluorescence In Situ Hybridization (FISH), Other Technologies), By Disease (Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Prostate Cancer, Other Cancer Types), By Sample Type (Tissue Biopsy, Liquid Biopsy), By End-User (Hospitals and Cancer Centers, Pathology and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutions) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Oncology Companion Diagnostic Industry Overview
Precision Oncology Is Driving Rapid Expansion of Companion Diagnostic Technologies
The oncology companion diagnostic industry is undergoing substantial expansion as precision medicine becomes increasingly integrated into cancer treatment decision-making. Advances in molecular pathology, immunohistochemistry, liquid biopsy technologies, and biomarker-guided therapeutics are reshaping oncology care pathways by enabling the identification of patient populations most likely to benefit from targeted treatments. Regulatory agencies are increasingly approving companion diagnostics alongside novel therapeutics, reinforcing the importance of co-development strategies between pharmaceutical and diagnostic companies. The industry continues to transition toward highly personalized treatment paradigms in which biomarker characterization serves as a prerequisite for therapeutic selection, treatment monitoring, and clinical trial enrollment.
Biomarker-Driven Prostate Cancer Treatment Is Accelerating Companion Diagnostic Adoption
The growing use of molecular biomarkers in prostate cancer management has created significant opportunities for companion diagnostic developers and targeted therapy manufacturers. Identification of genomic and protein expression abnormalities enables clinicians to match patients with increasingly sophisticated precision therapeutics while improving treatment outcomes. This trend was reinforced by the U.S. FDA approval of the VENTANA PTEN (SP218) RxDx Assay developed by Roche, representing the first immunohistochemistry-based companion diagnostic approved for detecting PTEN protein deficiency in prostate cancer tissue. The assay identifies patients with metastatic androgen pathway modulation-na?ve or sensitive prostate adenocarcinoma exhibiting PTEN loss, allowing appropriate treatment selection with the newly approved targeted therapy TRUQAP (capivasertib) in combination with abiraterone. In parallel, Foundation Medicine will deploy the assay across its molecular testing infrastructure, further expanding access to biomarker-guided prostate cancer management.
Liquid Biopsy Technologies Are Expanding Access to Precision Oncology Testing
Non-invasive molecular diagnostics continue to transform oncology testing by providing rapid, accessible alternatives to traditional tissue biopsies. Liquid biopsy technologies offer significant advantages in patients with advanced cancers where tissue acquisition may be challenging or impractical. This evolution was demonstrated by the FDA approval of the Guardant360 CDx assay developed by Guardant Health as a companion diagnostic for HERNEXEOS (zongertinib), developed by Boehringer Ingelheim. The liquid biopsy assay identifies patients with advanced or metastatic non-squamous non-small cell lung cancer harboring specific HER2 (ERBB2) tyrosine kinase domain activating mutations through the analysis of circulating tumor DNA obtained from peripheral blood samples. This approach reduces dependence on invasive tissue biopsy procedures while enabling more efficient identification of eligible patients for targeted therapy interventions.
Co-Development of Therapeutics and Diagnostics Is Becoming a Standard Industry Model
The oncology ecosystem increasingly relies on simultaneous development of targeted therapeutics and companion diagnostics to maximize clinical efficacy and regulatory success. Pharmaceutical and diagnostic companies are designing biomarker-driven clinical trials that incorporate real-time patient stratification throughout the development process. This strategy was exemplified by the FDA approval of TRUQAP (capivasertib), developed by AstraZeneca, in combination with abiraterone acetate and prednisone for advanced PTEN-deficient prostate cancer. The approval was supported by findings from the global Phase III CAPItello-281 study involving 1,012 patients, where enrollment was guided by biomarker assessment using the VENTANA PTEN (SP218) RxDx assay. The targeted treatment regimen demonstrated a statistically significant 19% reduction in the risk of radiographic progression or death and extended median radiographic progression-free survival to 33.2 months compared with 25.7 months in the control arm, further validating the clinical and commercial importance of integrated companion diagnostic development strategies.
Oncology Companion Diagnostic Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Oncology Companion Diagnostic market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., bioM?rieux SA, Abbott Laboratories, Guardant Health, Inc., Leica Biosystems (Danaher Corporation). The Oncology Companion Diagnostic market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Oncology Companion Diagnostic industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Oncology Companion Diagnostic industry include- F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., bioM?rieux SA, Abbott Laboratories, Guardant Health, Inc., Leica Biosystems (Danaher Corporation). The Oncology Companion Diagnostic market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Oncology Companion Diagnostic Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Oncology Companion Diagnostic market remains one of the strongest-performing segments in the country.
The US Oncology Companion Diagnostic Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Oncology Companion Diagnostic market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Oncology Companion Diagnostic industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Oncology Companion Diagnostic markets
Canada's strong Oncology Companion Diagnostic sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Oncology Companion Diagnostic market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Oncology Companion Diagnostic Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Oncology Companion Diagnostic market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Oncology Companion Diagnostic population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Oncology Companion Diagnostic industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Oncology Companion Diagnostic market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Oncology Companion Diagnostic sales through 2034
France Oncology Companion Diagnostic companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Oncology Companion Diagnostic Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Oncology Companion Diagnostic distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Oncology Companion Diagnostic Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Oncology Companion Diagnostic market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Oncology Companion Diagnostic industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Oncology Companion Diagnostic industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Oncology Companion Diagnostic Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Oncology Companion Diagnostic market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Oncology Companion Diagnostic market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Oncology Companion Diagnostic Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Oncology Companion Diagnostic Market Segmentation
By Product and Service Type
Products
Services
By Technology Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH) / Fluorescence In Situ Hybridization (FISH)
Other Technologies
By Disease
Non-Small Cell Lung Cancer (NSCLC)
Breast Cancer
Colorectal Cancer
Leukemia
Melanoma
Prostate Cancer
Other Cancer Types
By Sample Type
Tissue Biopsy
Liquid Biopsy
By End-User
Hospitals and Cancer Centers
Pathology and Diagnostic Laboratories
Pharmaceutical and Biotechnology Companies
Academic and Research Institutions
Leading Companies in Oncology Companion Diagnostic Industry (2026)
F. Hoffmann-La Roche Ltd
Agilent Technologies, Inc.
Illumina, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Myriad Genetics, Inc.
bioM?rieux SA
Abbott Laboratories
Guardant Health, Inc.
Leica Biosystems (Danaher Corporation)
Countries Included
The Oncology Companion Diagnostic market report provides detailed analysis and outlook of Oncology Companion Diagnostic segments including By Product and Service Type (Products, Services ), By Technology Type (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), In Situ Hybridization (ISH) / Fluorescence In Situ Hybridization (FISH), Other Technologies), By Disease (Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Prostate Cancer, Other Cancer Types), By Sample Type (Tissue Biopsy, Liquid Biopsy), By End-User (Hospitals and Cancer Centers, Pathology and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutions) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Oncology Companion Diagnostic Industry Overview
Precision Oncology Is Driving Rapid Expansion of Companion Diagnostic Technologies
The oncology companion diagnostic industry is undergoing substantial expansion as precision medicine becomes increasingly integrated into cancer treatment decision-making. Advances in molecular pathology, immunohistochemistry, liquid biopsy technologies, and biomarker-guided therapeutics are reshaping oncology care pathways by enabling the identification of patient populations most likely to benefit from targeted treatments. Regulatory agencies are increasingly approving companion diagnostics alongside novel therapeutics, reinforcing the importance of co-development strategies between pharmaceutical and diagnostic companies. The industry continues to transition toward highly personalized treatment paradigms in which biomarker characterization serves as a prerequisite for therapeutic selection, treatment monitoring, and clinical trial enrollment.
Biomarker-Driven Prostate Cancer Treatment Is Accelerating Companion Diagnostic Adoption
The growing use of molecular biomarkers in prostate cancer management has created significant opportunities for companion diagnostic developers and targeted therapy manufacturers. Identification of genomic and protein expression abnormalities enables clinicians to match patients with increasingly sophisticated precision therapeutics while improving treatment outcomes. This trend was reinforced by the U.S. FDA approval of the VENTANA PTEN (SP218) RxDx Assay developed by Roche, representing the first immunohistochemistry-based companion diagnostic approved for detecting PTEN protein deficiency in prostate cancer tissue. The assay identifies patients with metastatic androgen pathway modulation-na?ve or sensitive prostate adenocarcinoma exhibiting PTEN loss, allowing appropriate treatment selection with the newly approved targeted therapy TRUQAP (capivasertib) in combination with abiraterone. In parallel, Foundation Medicine will deploy the assay across its molecular testing infrastructure, further expanding access to biomarker-guided prostate cancer management.
Liquid Biopsy Technologies Are Expanding Access to Precision Oncology Testing
Non-invasive molecular diagnostics continue to transform oncology testing by providing rapid, accessible alternatives to traditional tissue biopsies. Liquid biopsy technologies offer significant advantages in patients with advanced cancers where tissue acquisition may be challenging or impractical. This evolution was demonstrated by the FDA approval of the Guardant360 CDx assay developed by Guardant Health as a companion diagnostic for HERNEXEOS (zongertinib), developed by Boehringer Ingelheim. The liquid biopsy assay identifies patients with advanced or metastatic non-squamous non-small cell lung cancer harboring specific HER2 (ERBB2) tyrosine kinase domain activating mutations through the analysis of circulating tumor DNA obtained from peripheral blood samples. This approach reduces dependence on invasive tissue biopsy procedures while enabling more efficient identification of eligible patients for targeted therapy interventions.
Co-Development of Therapeutics and Diagnostics Is Becoming a Standard Industry Model
The oncology ecosystem increasingly relies on simultaneous development of targeted therapeutics and companion diagnostics to maximize clinical efficacy and regulatory success. Pharmaceutical and diagnostic companies are designing biomarker-driven clinical trials that incorporate real-time patient stratification throughout the development process. This strategy was exemplified by the FDA approval of TRUQAP (capivasertib), developed by AstraZeneca, in combination with abiraterone acetate and prednisone for advanced PTEN-deficient prostate cancer. The approval was supported by findings from the global Phase III CAPItello-281 study involving 1,012 patients, where enrollment was guided by biomarker assessment using the VENTANA PTEN (SP218) RxDx assay. The targeted treatment regimen demonstrated a statistically significant 19% reduction in the risk of radiographic progression or death and extended median radiographic progression-free survival to 33.2 months compared with 25.7 months in the control arm, further validating the clinical and commercial importance of integrated companion diagnostic development strategies.
Oncology Companion Diagnostic Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Oncology Companion Diagnostic market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., bioM?rieux SA, Abbott Laboratories, Guardant Health, Inc., Leica Biosystems (Danaher Corporation). The Oncology Companion Diagnostic market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Oncology Companion Diagnostic industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Oncology Companion Diagnostic Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Oncology Companion Diagnostic companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Oncology Companion Diagnostic markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Oncology Companion Diagnostic industry include- F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., bioM?rieux SA, Abbott Laboratories, Guardant Health, Inc., Leica Biosystems (Danaher Corporation). The Oncology Companion Diagnostic market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Oncology Companion Diagnostic Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Oncology Companion Diagnostic market remains one of the strongest-performing segments in the country.
The US Oncology Companion Diagnostic Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Oncology Companion Diagnostic market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Oncology Companion Diagnostic industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Oncology Companion Diagnostic markets
Canada's strong Oncology Companion Diagnostic sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Oncology Companion Diagnostic market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Oncology Companion Diagnostic Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Oncology Companion Diagnostic market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Oncology Companion Diagnostic population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Oncology Companion Diagnostic industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Oncology Companion Diagnostic market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Oncology Companion Diagnostic sales through 2034
France Oncology Companion Diagnostic companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Oncology Companion Diagnostic Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Oncology Companion Diagnostic distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Oncology Companion Diagnostic Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Oncology Companion Diagnostic market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Oncology Companion Diagnostic industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Oncology Companion Diagnostic industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Oncology Companion Diagnostic Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Oncology Companion Diagnostic market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Oncology Companion Diagnostic market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Oncology Companion Diagnostic Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Oncology Companion Diagnostic Market Segmentation
By Product and Service Type
Products
Services
By Technology Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH) / Fluorescence In Situ Hybridization (FISH)
Other Technologies
By Disease
Non-Small Cell Lung Cancer (NSCLC)
Breast Cancer
Colorectal Cancer
Leukemia
Melanoma
Prostate Cancer
Other Cancer Types
By Sample Type
Tissue Biopsy
Liquid Biopsy
By End-User
Hospitals and Cancer Centers
Pathology and Diagnostic Laboratories
Pharmaceutical and Biotechnology Companies
Academic and Research Institutions
Leading Companies in Oncology Companion Diagnostic Industry (2026)
F. Hoffmann-La Roche Ltd
Agilent Technologies, Inc.
Illumina, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Myriad Genetics, Inc.
bioM?rieux SA
Abbott Laboratories
Guardant Health, Inc.
Leica Biosystems (Danaher Corporation)
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Oncology Companion Diagnostic Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Oncology Companion Diagnostic Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Oncology Companion Diagnostic Markets in 2026
3.2. Global Historic and Forecast Oncology Companion Diagnostic Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Oncology Companion Diagnostic Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Oncology Companion Diagnostic Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Oncology Companion Diagnostic Value Chain
CHAPTER 4- ONCOLOGY COMPANION DIAGNOSTIC MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Oncology Companion Diagnostic Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- ONCOLOGY COMPANION DIAGNOSTIC MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product and Service Type
Products
Services
By Technology Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH) / Fluorescence In Situ Hybridization (FISH)
Other Technologies
By Disease
Non-Small Cell Lung Cancer (NSCLC)
Breast Cancer
Colorectal Cancer
Leukemia
Melanoma
Prostate Cancer
Other Cancer Types
By Sample Type
Tissue Biopsy
Liquid Biopsy
By End-User
Hospitals and Cancer Centers
Pathology and Diagnostic Laboratories
Pharmaceutical and Biotechnology Companies
Academic and Research Institutions
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA ONCOLOGY COMPANION DIAGNOSTIC MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Oncology Companion Diagnostic Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Oncology Companion Diagnostic Market Trends and Growth Opportunities to 2034
7.5. North America Oncology Companion Diagnostic Market Size Outlook by Type
7.6. North America Oncology Companion Diagnostic Market Size Outlook by Application
7.7. North America Oncology Companion Diagnostic Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Oncology Companion Diagnostic Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Oncology Companion Diagnostic Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Oncology Companion Diagnostic Companies
CHAPTER 8- EUROPE ONCOLOGY COMPANION DIAGNOSTIC MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Oncology Companion Diagnostic Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Oncology Companion Diagnostic Market Trends and Growth Opportunities to 2034
8.5. Europe Oncology Companion Diagnostic Market Size Outlook by Type
8.6. Europe Oncology Companion Diagnostic Market Size Outlook by Application
8.7. Europe Oncology Companion Diagnostic Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Oncology Companion Diagnostic Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Oncology Companion Diagnostic Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Oncology Companion Diagnostic Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Oncology Companion Diagnostic Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Oncology Companion Diagnostic Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Oncology Companion Diagnostic Companies
CHAPTER 9- ASIA PACIFIC ONCOLOGY COMPANION DIAGNOSTIC MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Oncology Companion Diagnostic Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Oncology Companion Diagnostic Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Oncology Companion Diagnostic Market Size Outlook by Type
9.6. Asia Pacific Oncology Companion Diagnostic Market Size Outlook by Application
9.7. Asia Pacific Oncology Companion Diagnostic Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Oncology Companion Diagnostic Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Oncology Companion Diagnostic Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Oncology Companion Diagnostic Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Oncology Companion Diagnostic Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Oncology Companion Diagnostic Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Oncology Companion Diagnostic Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA ONCOLOGY COMPANION DIAGNOSTIC MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Oncology Companion Diagnostic Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Oncology Companion Diagnostic Market Trends and Growth Opportunities to 2034
10.5. South and Central America Oncology Companion Diagnostic Market Size Outlook by Type
10.6. South and Central America Oncology Companion Diagnostic Market Size Outlook by Application
10.7. South and Central America Oncology Companion Diagnostic Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Oncology Companion Diagnostic Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Oncology Companion Diagnostic Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Oncology Companion Diagnostic Companies
CHAPTER 11- MIDDLE EAST AND AFRICA ONCOLOGY COMPANION DIAGNOSTIC MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Oncology Companion Diagnostic Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Oncology Companion Diagnostic Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Oncology Companion Diagnostic Market Size Outlook by Type
11.6. Middle East and Africa Oncology Companion Diagnostic Market Size Outlook by Application
11.7. Middle East and Africa Oncology Companion Diagnostic Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Oncology Companion Diagnostic Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Oncology Companion Diagnostic Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Oncology Companion Diagnostic Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Oncology Companion Diagnostic Industry
F. Hoffmann-La Roche Ltd
Agilent Technologies, Inc.
Illumina, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Myriad Genetics, Inc.
bioM?rieux SA
Abbott Laboratories
Guardant Health, Inc.
Leica Biosystems (Danaher Corporation)
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Oncology Companion Diagnostic Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Oncology Companion Diagnostic Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Oncology Companion Diagnostic Markets in 2026
3.2. Global Historic and Forecast Oncology Companion Diagnostic Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Oncology Companion Diagnostic Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Oncology Companion Diagnostic Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Oncology Companion Diagnostic Value Chain
CHAPTER 4- ONCOLOGY COMPANION DIAGNOSTIC MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Oncology Companion Diagnostic Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- ONCOLOGY COMPANION DIAGNOSTIC MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product and Service Type
Products
Services
By Technology Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH) / Fluorescence In Situ Hybridization (FISH)
Other Technologies
By Disease
Non-Small Cell Lung Cancer (NSCLC)
Breast Cancer
Colorectal Cancer
Leukemia
Melanoma
Prostate Cancer
Other Cancer Types
By Sample Type
Tissue Biopsy
Liquid Biopsy
By End-User
Hospitals and Cancer Centers
Pathology and Diagnostic Laboratories
Pharmaceutical and Biotechnology Companies
Academic and Research Institutions
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA ONCOLOGY COMPANION DIAGNOSTIC MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Oncology Companion Diagnostic Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Oncology Companion Diagnostic Market Trends and Growth Opportunities to 2034
7.5. North America Oncology Companion Diagnostic Market Size Outlook by Type
7.6. North America Oncology Companion Diagnostic Market Size Outlook by Application
7.7. North America Oncology Companion Diagnostic Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Oncology Companion Diagnostic Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Oncology Companion Diagnostic Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Oncology Companion Diagnostic Companies
CHAPTER 8- EUROPE ONCOLOGY COMPANION DIAGNOSTIC MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Oncology Companion Diagnostic Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Oncology Companion Diagnostic Market Trends and Growth Opportunities to 2034
8.5. Europe Oncology Companion Diagnostic Market Size Outlook by Type
8.6. Europe Oncology Companion Diagnostic Market Size Outlook by Application
8.7. Europe Oncology Companion Diagnostic Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Oncology Companion Diagnostic Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Oncology Companion Diagnostic Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Oncology Companion Diagnostic Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Oncology Companion Diagnostic Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Oncology Companion Diagnostic Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Oncology Companion Diagnostic Companies
CHAPTER 9- ASIA PACIFIC ONCOLOGY COMPANION DIAGNOSTIC MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Oncology Companion Diagnostic Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Oncology Companion Diagnostic Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Oncology Companion Diagnostic Market Size Outlook by Type
9.6. Asia Pacific Oncology Companion Diagnostic Market Size Outlook by Application
9.7. Asia Pacific Oncology Companion Diagnostic Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Oncology Companion Diagnostic Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Oncology Companion Diagnostic Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Oncology Companion Diagnostic Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Oncology Companion Diagnostic Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Oncology Companion Diagnostic Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Oncology Companion Diagnostic Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA ONCOLOGY COMPANION DIAGNOSTIC MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Oncology Companion Diagnostic Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Oncology Companion Diagnostic Market Trends and Growth Opportunities to 2034
10.5. South and Central America Oncology Companion Diagnostic Market Size Outlook by Type
10.6. South and Central America Oncology Companion Diagnostic Market Size Outlook by Application
10.7. South and Central America Oncology Companion Diagnostic Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Oncology Companion Diagnostic Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Oncology Companion Diagnostic Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Oncology Companion Diagnostic Companies
CHAPTER 11- MIDDLE EAST AND AFRICA ONCOLOGY COMPANION DIAGNOSTIC MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Oncology Companion Diagnostic Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Oncology Companion Diagnostic Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Oncology Companion Diagnostic Market Size Outlook by Type
11.6. Middle East and Africa Oncology Companion Diagnostic Market Size Outlook by Application
11.7. Middle East and Africa Oncology Companion Diagnostic Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Oncology Companion Diagnostic Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Oncology Companion Diagnostic Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Oncology Companion Diagnostic Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Oncology Companion Diagnostic Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Oncology Companion Diagnostic Industry
F. Hoffmann-La Roche Ltd
Agilent Technologies, Inc.
Illumina, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Myriad Genetics, Inc.
bioM?rieux SA
Abbott Laboratories
Guardant Health, Inc.
Leica Biosystems (Danaher Corporation)
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
